Loading...
Thiazolidinediones (TZDs) reduce osteoblastic activity, and recent clinical studies suggest that TZD use raises risk for fractures. In a population-based, case-control study from the U.K., researchers compared fracture risk of TZD users versus that of users of other oral diabetic agents. Participants were 1020 patients with diabetes and low-trauma fracture and 3728 controls with diabetes and no fracture; 6% of cases and 5% of controls had received TZDs.
After controlling for potential confounders, fracture risk was higher (odds ratio, 2.4) for current users of TZDs (corresponding to 12–18 months of treatment) than for those taking other antidiabetes medications. This risk extended equally to both sexes and all ages and did not distinguish be…